

Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the Application.

Listing of the Claims:

Claim 1 (Newly Amended) A therapeutic method for treating blepharitis, post-operative inflammation and pain from corneal transplant surgery, endophthalmitis, episcleritis, keratitis, keratoconjunctivitis, keratoconjunctivitis sicca, post-operative inflammation and pain from lens implantation surgery, Mooren's ulcer and post-operative inflammation and pain from retinal detachment an ocular COX-2 mediated disorder, the method comprising administering an ocular COX-2 mediated disorder-effective amount of a COX-2 inhibitor compound or prodrug thereof, the COX-2 inhibitor selected from the group consisting of celecoxib, deracoxib, valdecoxib, parecoxib, a benzopyran COX-2 inhibitor, rofecoxib, etoricoxib, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one and 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-[4-(methyl-sulfonyl)-phenyl]-3(2H)-pyridazinone, JTE-522, DuP 697, ABT-963, and L-776,967.

Claim 2-3 (Canceled)

Claim 4. (Previously Amended) The therapeutic method of Claim 1 wherein the COX-2 inhibitor is celecoxib.

Claim 5 (Previously Amended) The therapeutic method of
Claim 1 wherein the COX-2 inhibitor is deracoxib.

Claim 6 (Previously Amended) The therapeutic method of
Claim 1 wherein the COX-2 inhibitor is valdecoxib.

Claim 7 (Previously Amended) The therapeutic method of
Claim 1 wherein the COX-2 inhibitor is a benzopyran
COX-2 inhibitor.

Claim 8 (Previously Amended) The therapeutic method of
Claim 1 wherein the COX-2 inhibitor is rofecoxib.

Claim 9 (Previously Amended) The therapeutic method of
Claim 1 wherein the COX-2 inhibitor is etoricoxib.

Claim 10 (Previously Amended) The therapeutic method of
Claim 1 wherein the COX-2 inhibitor is 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one.

Claim 11 (Previously Amended) The therapeutic method of
Claim 1 wherein the COX-2 inhibitor is 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

Claim 12 (Canceled)

Claim 13 (Previously Amended) The therapeutic method of
Claim 1 wherein the prodrug of the COX-2 inhibitor is parecoxib.

Claim 14 (Previously Amended) The therapeutic method of
Claim 1 wherein the ocular COX-2 mediated disorder is
Mooren's ulcer.

Claim 15 (Previously Amended) The therapeutic method of
Claim 1 wherein the COX-2 inhibitor further comprises
one or more ophthalmically acceptable excipient
ingredients that reduce the rate of removal of the
composition from the eye by lacrimation such that the
composition has an effective residence time in the eye
of about 2 to about 24 hours.

Claim 16-39 (Canceled)